Global Myasthenia Gravis Treatment Market
Myasthenia gravis (MG) is a type of chronic autoimmune neuromuscular disease that is known to cause weakness in skeletal muscles, mostly in the arms and legs. Double vision, facial paralysis, difficulty in walking, and dropping of eyelids are some of the common symptoms of myasthenia gravis. This condition is generally diagnosed by tests like repetitive nerve stimulation test, blood test for antibodies, edrophonium test, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI). Corticosteroids drugs (azathioprine, and cyclosporine) and Acetylcholine esterase inhibitors (Edrophonium, and Pyridostigmine) are specifically used for the treatment of this condition.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/2625
Global Myasthenia Gravis Treatment Market – Drivers & Restraints
Consistent R&D activities are expected to propel the growth of the global myasthenia gravis treatment market. For instance, in October 2017, Alexion Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration for Soliris which contains eculizumab as an active component. This drug is used for treatment of antibody positive generalized myasthenia gravis, and also finds pivotal use in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS).
Furthermore, growing number of clinical trials for treatment of myasthenia gravis are expected to drive the myasthenia gravis treatment market growth. For instance, in December 2017, Novartis AG initiated phase II clinical trial of CFZ533 for treatment of severe myasthenia gravis. The main function of CFZ533 is the modification of immune response by deactivation of white blood cells. Hence, it is expected to help with improvement and management of severe MG.
Moreover, Argenx BVBA is conducting a clinical phase III study of ARGX-113 for treatment of generalized myasthenia gravis. ARGX-113, also named Efgartigimod, is administered intravenously. The study started in March 2019 and is expected to complete in June 2021.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2625
However, the side effects of the drugs used for MG treatment are predicted to impede the growth of the global myasthenia gravis treatment market in the approaching years. According to a report issued by BioNews Services, LLC, in April 2019, a high-dose combination of cholinesterase inhibitors (ChEIs) and calcineurine inhibitors (CNIs), such as Mestinon and Prograf, is responsible for severe muscle cramps in myasthenia gravis patients. Hence, this factor is likely to constrain the global market expansion.
Global Myasthenia Gravis Treatment Market – Regional Analysis
North America is expected to hold a dominant position in the global myasthenia gravis treatment market over the projected period. The regional market growth is accredited to the burgeoning prevalence of myasthenia gravis in the region, particularly in the U.S. According to the National Center for Biotechnology Information (NCBI), in 2018, incidence rate of myasthenia gravis was estimated to be up to 5 to 30 cases per million people in the U.S.
Furthermore, Asia Pacific is projected to witness significant growth in the global myasthenia gravis treatment market, owing to increasing research and development activities for treatment of myasthenia gravis. For instance, Sun Yat-Sen University in China is conducting phase III clinical trial of Azathioprine and Leflunomide for treatment of myasthenia gravis.
Global Myasthenia Gravis Treatment Market – Leading Players
The key players operating in the global myasthenia gravis treatment market are Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Valeant Pharmaceutical International, Inc. Alexion Pharmaceutical Inc., F. Hoffmann-La Roche AG, CSL Behring, Baxter International, Inc., Shire Plc, and Avadel Pharmaceutical, PLC.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/myasthenia-gravis-treatment-market-2625
By Medication Type,
- Cholinesterase Inhibitors
- Intravenous immunoglobulin (IVIg)
- Monoclonal Antibody
By Distribution Channel,
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027